Paige Bischoff, Senior VP of Global Public Affairs, Alliance for Regenerative Medicine (ARM), Washington, D.C., discusses the future of the policy and regulatory landscape for advanced therapy medicinal products (ATMPs) in the European Union (EU) and how ARM aims to support the sector’s growth in the coming years. She describes the importance of implementing innovative payment models for ATMPs in Europe and how the use of real-world evidence should be incorporated into health technology assessment (HTA) frameworks going forward. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.